Loading
A phase 2 trial of Temozolomide in glioma & glioblastoma, run by Diakonos Oncology Corporation, now recruiting.
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) is a phase 2 interventional study registered as NCT06805305 by Diakonos Oncology Corporation, with 180 participants planned, started 2025-03-17 and due to reach its primary completion in 2030-03. Interventions recorded: DOC1021, Tumor resection, Temodar (Temozolomide) and SOC cranial radiation.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares DOC1021, Diakonos Oncology and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/